Table 1 Demographics and clinical characteristics of Behçet’s disease (BD) patients
From: Metabolomic alterations associated with Behçet’s disease
Parameter | Value |
|---|---|
Age (years), mean ± SD | 35.83 ± 11.96 |
Age at BD diagnosis (years), median (range) | 28.5 (17–60) |
Disease duration (months), median (range) | 120(13–379) |
BDCAF, median (range) | 10 (3–33) |
Clinical features of BD | |
Oral ulcer | 24 (100%) |
Genital ulcer | 17 (70.8%) |
Skin lesions | 16 (66.7%) |
Ocular lesions | 8 (33.3%) |
Vascular involvement | 7 (29.2%) |
Pathergy reaction | 5 (20.8%) |
Gastrointestinal involvement | 3 (12.5%) |
Neurologic involvement | 1 (4.2%) |
Erythrocyte sedimentation rate (mm/h), median (range) | 15.5 (2–76) |
C-reactive protein (mg/L), median (range) | 9.62 (0.56–53.1) |
Treatment-naive | 7 (29.2%) |
Current medications | |
Glucocorticoid | 15 (62.5%) |
Thalidomide | 13 (54.2%) |
Cyclophosphamide | 11 (45.8%) |
Salazosulfapyridine | 3 (12.5%) |
Cyclosporine A | 2 (8.3%) |
Methotrexate | 2(8.3%) |
Azathioprine | 1 (4.2%) |
Etanercept | 1 (4.2%) |